First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now be prescribed with insulin to treat overweight patients with type I diabetes inadequately controlled on insulin alone.

by Lisa Lytle
Dapagliflozin may be used as an adjunct to insulin when insulin alone does not provide adequate glycaemic control. | iStock.com/agrobacter
Dapagliflozin may be used as an adjunct to insulin when insulin alone does not provide adequate glycaemic control. | iStock.com/agrobacter

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package